NYSE: AEON · Life Sciences · 5 alerts · CIK 1837607
Share price
$0.1407Close, Nov 16
Market cap
$11.8M
Shares outstanding
84.12MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Aeon Biopharma, Inc. filings on SEC EDGAR ↗
AEON Biopharma reported a net loss of $10.5 million for the nine months ended September 30, 2026, compared to a $2.1 million loss in the prior year period. The company significantly strengthened its balance sheet through public offerings and PIPE financing, increasing cash and cash equivalents to $11.4 million and reducing total liabilities from $60.6 million to $11.7 million.
AEON Biopharma reported Q3 2026 financial results and provided a regulatory update on its ABP-450 biosimilar program. The company received FDA Type 2b feedback clarifying its development strategy and submitted an IND for a comparative pharmacodynamic study planned for Q1 2027.
Term
Q3 2026
“Over the past several months, we have made important progress in advancing the scientific and regulatory foundation for ABP-450’s development as a biosimilar to BOTOX®.”
Rob Bancroft, President and Chief Executive Officer
“With our CMAP IND submitted and additional capital secured through the recent milestone warrant exercises, we are positioned to advance the next phase of development, including the planned initiation of our comparative pharmacodynamic study in the first quarter of 2027.”
Rob Bancroft, President and Chief Executive Officer
AEON Biopharma entered into a warrant amendment to reduce the exercise price of its outstanding two-year milestone warrants from $0.3221 to $0.20 per share. Certain holders have agreed to exercise their warrants at this reduced price, which is expected to generate approximately $6.2 million in gross proceeds for the company. The warrants were triggered for accelerated expiration following FDA feedback on the company's ABP-450 biosimilar pathway and will expire on November 16, 2026.
AEON Biopharma made available a new corporate presentation on its website and filed it as an exhibit to its 8-K. The presentation outlines the company's strategy to disrupt the $3.5 billion neurotoxin market with its lead candidate, ABP-450, and provides updates on its regulatory pathway and clinical milestones.
AEON Biopharma received official minutes from a Type 2b meeting with the FDA regarding the biosimilar development pathway for ABP-450, a proposed biosimilar to BOTOX. The FDA agreed in principle with a proposed two-stage pharmacodynamic study design, and the company plans to submit an IND for this study in Q4 2026 with initiation expected in Q1 2027. The feedback supports a potentially streamlined development path that may leverage existing comparative human evidence to avoid or narrow the scope of standalone comparative efficacy studies.